Navigation Links
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2014
Date:11/14/2013

HONG KONG, Nov. 14, 2013 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2014, which ended September 30, 2013.

Second Quarter of Fiscal 2014 Highlights

  • Revenues for the second quarter of fiscal 2014 increased by 10.3% to RMB141.6 million ($23.1 million) from RMB128.5 million in the prior year period.
  • New subscriber sign-ups and accumulated subscriber base were 15,928 and 343,170, respectively.
  • Gross profit increased by 12.7% to RMB114.3 million ($18.7 million) from RMB101.4 million in the prior year period.
  • Gross margin was 80.7%, compared to 78.9% in the prior year period.
  • Operating income increased by 19.7% to RMB56.3 million ($9.2 million) from RMB47.0 million in the prior year period.
  • Interest expense amounted to RMB16.5 million ($2.7 million), which was largely attributable to the convertible notes issued to KKR China Healthcare Investment Limited ("KKR") and Golden Meditech Holdings Limited ("Golden Meditech").
  • Net income attributable to the Company's shareholders increased by 0.8% to RMB24.9 million ($4.1 million) from RMB24.7 million in the prior year period, after taking into account higher income tax expense in the second quarter.
  • Operating cash flow for the quarter amounted to RMB121.0 million ($19.8 million), after taking into account the coupon payment made to the Company's convertible note holder.
  • First Half of Fiscal 2014 Highlights

  • Revenues for the first half of fiscal 2014 increased by 10.9% to RMB270.4 million ($44.2 million) from RMB243.8 million in the prior year period.
  • New subscriber sign-up reached 31,188 and accumulated subscriber base expanded to 343,170.
  • Gross profit increased by 13.6% to RMB218.5 million ($35.7 million) from RMB192.3 million in the prior year period.
  • Operating income increased by 11.7% to RMB102.2 million ($16.7 million) from RMB91.4 million in the prior year period.
  • Interest expense amounted to RMB31.2 million ($5.1 million), compared to RMB24.3 million in the prior year period.
  • Net income attributable to the Company's shareholders amounted to RMB57.8 million ($9.4 million), compared to RMB55.8 million in the prior year period.
  • Operating cash flow for the first half of fiscal 2014 was RMB229.6 million ($37.5 million), after taking into account the coupon payment made to the Company's convertible note holders.
  • "We are glad that our second quarter performance continued to track management's expectations with moderate sequential growth in new subscriber numbers, as the overall markets began to transition away from the Dragon year after-effect. During the second quarter, we continued to build brand awareness and emphasize service quality in our business. This aligns with our premium pricing initiative, backed by our AABB accreditation, that began in April this year," stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.

    Summary - The Second Quarter and First Half Ended September 30, 2012 and 2013Three Months Ended September 30,

    Six Months Ended September 30,2012201320122013(in thousands)RMBRMBUS$RMBRMBUS$Revenues128,462141,63523,143243,792270,35644,176Gross Profit101,405114,27518,672192,346218,50435,703Operating Income47,04456,2909,19891,442102,17016,694Net Income Attributable to the Company's

    Shareholders24,69524,9044,06955,78857,8109,446Earnings per Ordinary Shares 
    - Basic1 and Diluted (RMB/US$)
    0.340.330.05 

    0.750.730.12Revenue Breakdown (%)Processing Fees76.4%71.6% 

    75.9%70.6%Storage Fees23.6%28.4% 

    24.1%29.4%New Subscribers (persons)18,49115,928 

    34,95131,188Total Accumulated Subscribers (persons)274,705 

    343,170 

    274,705343,170[1] The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into consideration the effect of such participating rights of RMB0.01($0.002) and RMB0.06($0.01) for the three months and six months ended September 30, 2013, respectively.Summary - Selected Cash Flow Statement ItemsThree Months EndedSix Months EndedSeptember 30, 2013September 30, 2013(in thousands)RMBUS$RMBUS$Net cash provided by operating activities120,96919,766229,62337,521Net cash used in investing activities(17,531)(2,865)(56,891)(9,296)Net cash provided by financing activities5,5789112,336381Second Quarter of Fiscal 2014 Financial ResultsREVENUES. Revenues increased by 10.3% to RMB141.6 million ($23.1 million) in the second quarter of fiscal 2014 from RMB128.5 million in the prior year period, driven mainly by higher pricing implemented since the previous quarter and the expansion in the Company's accumulated subscriber base, overcoming the year-over-year declines in new subscriber numbers due to the Dragon year after-effect.

    Revenues generated from storage fees increased to RMB40.2 million ($6.6 million), up 32.7% from RMB30.3 million in the prior year period. Because of the increased accumulated subscriber base, revenue from storage fees accounted for 28.4% of total revenues, compared to 23.6% in the prior year period.

    Revenues generated from processing fees in this quarter were RMB101.4 million ($16.5 million), up modestly from RMB98.2 million in the prior year period as pricing increases countered the impact of year-over-year declines in new subscriber numbers. 15,928 new subscriber sign-ups were recorded during the second quarter of fiscal 2014, representing a 13.9% year-over-year decrease but a 4.4% sequential increase. Revenues generated from processing fees accounted for 71.6% of total revenues, compared to 76.4% in the prior year period.

    GROSS PROFIT. Gross profit for the second quarter of fiscal 2014 increased by 12.7% to RMB114.3 million ($18.7 million) from RMB101.4 million in the prior year period, as the benefits of economies of scale and higher price levels outweighed higher raw material costs. Gross margin was 80.7%, compared to 78.9% in the prior year period.

    OPERATING INCOME. Operating income for the second quarter increased 19.7% to RMB56.3 million ($9.2 million) compared to RMB47.0 million in the prior year period. Operating margin improved to 39.7% from 36.6% in the prior year period as a result of higher gross margin and effective cost controls. Depreciation and amortization expenses for the second quarter were RMB8.7 million ($1.4 million), compared to RMB8.3 million in the prior year period.

    Research and Development Expenses. Research and development expenses, which have been stable in the last few quarters, were RMB2.3 million ($0.4 million).

    Sales and Marketing Expenses. Sales and marketing expenses for the second quarter amounted to RMB27.6 million ($4.5 million), compared to RMB23.5 million in the prior year period. The increase in sales and marketing expenses continued to correlate with the increase in revenue. Aside from higher staff costs, additional expenses were incurred for the marketing effort in preparation for the large scale Zhejiang market launch. However, management continued to monitor sales and marketing expenses and maintained consistent level of cost efficiency through cost cutting and prudent spending. As a result, sales and marketing expenses as a percentage of revenue decreased to 19.5% of revenues from 22.1% in the first quarter of the current fiscal year.

    General and Administrative Expenses. General and administrative expenses were stable at RMB28.0 million ($4.6 million), compared to RMB29.0 million in the prior year period and RMB27.4 million in the first quarter of fiscal 2014. As a percentage of revenue, general and administrative expenses decreased to 19.8% compared to 22.6% in the prior year period and 21.3% in the first quarter of fiscal 2014.

    OTHER INCOME AND EXPENSES

    Interest Expense. Interest expense increased to RMB16.5 million ($2.7 million) from RMB14.1 million in the prior year period. The increase was largely attributable to the convertible note issued to Golden Meditech in the third quarter of fiscal 2013, offset in part by the capitalization of interest expense for the Company's in-progress construction of new facilities. Interest expense capitalized in the second quarter of fiscal 2014 amounted to RMB6.8 million ($1.1 million). No interest expense was capitalized in the prior year period.

    NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As the increase in income before tax was partially eroded by the increase in income tax expense, net income attributable to the Company's shareholders for the second quarter of fiscal 2014 increased by 0.8% to RMB24.9 million ($4.1 million) from RMB24.7 million in the prior year period. Net margin for the second quarter of fiscal 2014 was 17.6%. EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend2. Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights of RMB0.01 ($0.002). Basic and diluted earnings per ordinary share for the second quarter of fiscal 2014 were RMB0.33 ($0.05).

    LIQUIDITY. As of September 30, 2013, the Company had cash and cash equivalents of RMB1,669.4 million ($272.8 million) compared to RMB1,494.1 million as of March 31, 2013. The Company had total debt of RMB814.8 million ($133.1 million) as of September 30, 2013. Operating cash flow for the quarter amounted to RMB121.0 million ($19.8 million), after taking into account the coupon payment made to the Company's convertible note holder.

    Ms. Zheng concluded, "The management continued to closely monitor the market impact of our upward pricing adjustment, and we are encouraged by the improvement in the number of new subscriber sign-ups which suggests the market has slowly adapted to the new pricing levels. At the same time, our capacity expansion in Guangdong and new facility development in Zhejiang are both well under way.  With the new facilities coming on-line by the end of the current fiscal year, we will be able to truly flex our marketing muscle and further penetrate the Guangdong market and the largely untapped Zhejiang market."

    [2] "Excess Cash Dividend" means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% in such financial year divided by the number of shares into which the note is convertible at the conversion price then in effect on the relevant record date.First Half of Fiscal 2014 Financial ResultsFor the first half of fiscal year 2014, total revenues increased by 10.9% to RMB270.4 million ($44.2 million) from RMB243.8 million in the prior year period. The increase was largely attributable to the implementation of the Company's new service pricing and the expansion of the Company's accumulated subscriber base to 343,170 subscribers, which partially offset the decrease in new subscriber numbers. Revenues from processing fees and storage fees grew by 3.1% and 35.4%, respectively. Gross profit increased by 13.6% to RMB218.5 million ($35.7 million) from RMB192.3 million in the prior year period. Operating income increased by 11.7% to RMB102.2 million ($16.7 million) from RMB91.4 million in the prior year period. Net income attributable to the Company's shareholders amounted to RMB57.8 million ($9.4 million). Basic and diluted earnings per share attributable to ordinary shares were RMB0.73 ($0.12). Net cash provided by operating activities in the first half of fiscal 2014 was RMB229.6 million ($37.5 million).

    Conference Call The Company will host a conference call at 8:00 a.m. ET on Friday, November 15, 2013 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 5266601.

    About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

    Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to confirm these statements to actual results, unless required by law.

    The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

    This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending September 30, 2013 were made at the noon buying rate of RMB6.1200 to $1.00 on September 30, 2013 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

    For more information, please contact:China Cord Blood Corporation
    Investor Relations Department
    Tel: (+852) 3605-8180
    Email: ir@chinacordbloodcorp.com

    ICR, Inc.
    Mr. William Zima
    Tel: (+86) 10-6583-7511
    U.S. Tel: (646) 405-5185
    Email: William.zima@icrinc.com

     

    CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSAs of March 31 and September 30, 2013March 31,September 30,20132013RMBRMBUS$(in thousands except share data)ASSETS
    Current assetsCash and cash equivalents1,494,0991,669,380272,775Accounts receivable, less allowance for doubtful accounts
    (March 31, 2013: RMB14,112; September 30, 2013: RMB16,082)
    73,07680,55913,163Inventories10,26516,8322,751Prepaid expenses and other receivables11,60214,8442,425Debt issuance costs3,6783,606589Deferred tax assets5,4545,985978Total current assets1,598,1741,791,206292,681Property, plant and equipment, net468,272520,16984,995Non-current prepayments212,633208,18834,018Non-current accounts receivable, less allowance for doubtful accounts
    (March 31, 2013: RMB36,361; September 30, 2013: 
    RMB38,346)249,370236,06438,572Inventories39,73042,9337,015Intangible assets, net125,170122,86020,075Available-for-sale equity securities88,404169,69927,729Other investment189,129189,12930,903Debt issuance costs11,6679,6301,574Deferred tax assets3,7271,114182Total assets2,986,2763,290,992537,744LIABILITIESCurrent liabilitiesBank loan50,00060,0009,804Accounts payable9,8908,7791,434Accrued expenses and other payables84,00664,94210,611Deferred revenue172,328181,42829,645Amounts due to related parties11,241720118Income tax payable4,9832,206360Deferred tax liabilities-1,300212Total current liabilities332,448319,37552,184Convertible notes751,781754,807123,334Non-current deferred revenue530,258665,226108,697Other non-current liabilities107,158133,95421,888Deferred tax liabilities23,16824,9384,075Total liabilities1,744,8131,898,300310,178EQUITYShareholders' equity of China Cord Blood CorporationOrdinary shares- US$0.0001 par value, 250,000,000 shares authorized,
    73,140,147 shares issued, and 73,003,248 shares outstanding
    as of March 31, 2013 and September 30, 2013, respectively
    50508Additional paid-in capital798,221798,221130,429Treasury stock, at cost(March 31, 2013 and September 30, 2013: 136,899 shares, respectively)(2,815)(2,815)(460)Accumulated other comprehensive income18,256111,40818,204Retained earnings423,420481,23078,633Total equity attributable to China Cord Blood Corporation1,237,1321,388,094226,814Non-controlling interests4,3314,598752Total equity1,241,4631,392,692227,566Total liabilities and equity2,986,2763,290,992537,744 

    CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEFor the Three Months and Six Months ended September 30, 2012 and 2013Three months ended September 30,Six months ended September 30,2012201320122013RMBRMBUS$

    RMBRMBUS$(in thousands except share data)Revenues
    128,462141,63523,143243,792270,35644,176Direct costs(27,057)(27,360)(4,471)(51,446)(51,852)(8,473)Gross profit101,405114,27518,672192,346218,50435,703Operating expensesResearch and development(1,860)(2,310)(377)(4,123)(4,833)(790)Sales and marketing(23,517)(27,633)(4,515)(42,737)(56,057)(9,160)General and administrative(28,984)(28,042)(4,582)(54,044)(55,444)(9,059)Total operating expenses(54,361)(57,985)(9,474)(100,904)(116,334)(19,009)Operating income47,04456,2909,19891,442102,17016,694Other expense, netInterest income3,8594,3127057,1888,4941,388Interest expense(14,089)(16,461)(2,690)(24,265)(31,219)(5,101)Exchange gain/(loss)41691151(55)(9)Dividend income---2,4208,7221,425Others(1,002)51484(766)1,044171Total other expense, net(11,191)(11,566)(1,890)(15,372)(13,014)(2,126)Income before income tax35,85344,7247,30876,07089,15614,568Income tax expense(8,466)(19,706)(3,220)(14,801)(31,079)(5,078)Net income27,38725,0184,08861,26958,0779,490Income attributable to non-controlling interests(2,692)(114)(19)(5,481)(267)(44)Net income attributable to China Cord Blood


    Corporation's shareholders24,69524,9044,06955,78857,8109,446Net income per share:Attributable to ordinary shares- Basic0.340.330.050.750.730.12- Diluted0.340.330.050.750.730.12Other comprehensive income- Net effect of foreign currency translation, net


    of nil tax
    (1,007)2,789456(2,424)9,5941,568- Net unrealized gain/(loss) in available-for-sale


    equity securities, net of nil tax
    2,62459,2209,676(19,950)83,55813,653Comprehensive income29,00487,02714,22038,895151,22924,711Comprehensive income attributable to non-


    controlling interests(2,672)(114)(19)(5,459)(267)(44)Comprehensive income attributable to China 


    Cord Blood Corporation's shareholders
    26,33286,91314,20133,436150,96224,667


    '/>"/>
    SOURCE China Cord Blood Corporation
    Copyright©2012 PR Newswire.
    All rights reserved


    Related biology technology :

    1. China Water-Soluble Dietary Fiber Market 2013-2017 Report
    2. China Synthetic Resin Industry Report, 2013-2016
    3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    4. Current Trends for Conducting Clinical Trials in China, New Life Science Webinar Hosted By Xtalks
    5. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
    6. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
    7. Silane Coupling Agent Industry 2013 Global & China Development Trend Analysis in a New Study at DeepResearchReports.com
    8. Ion-exchange Resin Market 2013 Global & China Trend Analysis in a New Research Available at DeepResearchReports.com
    9. Insecticides China News 1307 – New Research Available
    10. Bulletproof Security Glass Market in China 2012 - 2016: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Trends, Strategy and Forecast Research
    11. Humic Acid Industry 2013 China and Global Products Analysis in a New Research Report Available at DeepResearchReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , An increasing ... anticipated. Nanotechnology will be applied at all stages of drug ... in clinical trials. Many of the assays based on nanobiotechnology ...
    (Date:12/2/2016)... ... ... The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° ... 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr ... approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific ...
    (Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
    (Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
    Breaking Biology Technology:
    (Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
    (Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
    (Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
    Breaking Biology News(10 mins):